Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 254

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Weekly Psychedelic Policy Briefing: October 5, 2026

Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines

Psychedelic Churches Need Psychedelic Seminaries

How PCP Became A Weapon of Police Propaganda [Part 2]

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma...

Whole-Body Effects of Psychedelics Part 2 – Blood and Immune System

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its...

PT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and...

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose...

Cybin Files 14th Patent Application Further Strengthening its IP Portfolio and...

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update

Field Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks...

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic...

Weekly Psychedelic Policy Briefing: October 5, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©